Lupus Multiplex Registry & Repository (LMRR), sponsored by the National Institute of Arthritis, Musculoskeletal and Skin Diseases maintains information on families with two of more of their members who are suffering from SLE. Its aim is to help researchers discover the gene for lupus to help find new and better treatments for the disease.

AbstractAIM:It has been reported that tumor necrosis factor (TNF)-α plays dual controversial roles, beneficial or detrimental, in the pathogenesis of murinelupus nephritis (LN). However, its precise role in the development of human LN remains to be determined.

METHODS:We examine the effect of pretreatment with TNF-α on the toll-like receptor 3 (TLR3) signaling induced by polyinosinic-polycytidylic acid (poly IC), a synthetic analog of viral dsRNA that makes "pseudoviral" infection in cultured normal human mesangial cells, and analyzed the expression of CC chemokine ligand 5 (CCL5) via TLR3/interferon (IFN)-β/retinoic acid-inducible gene-I (RIG-I) pathway by reverse transcriptase-polymerase chain reaction, Western blotting and enzyme-linked immunosorbent assay.

RESULTS:We found synergistic effect of TNF-α, even at low level, on the expression of CCL5 induced by poly IC in a concentration-dependent manner, in comparison with that by poly IC alone. Knockdown of either IFN-β or RIG-I decreased CCL5 expression induced by TNF-α followed by poly IC.

CONCLUSION:Pretreatment with TNF-α leads marked activation of the TLR3/IFN-β/RIG-I/CCL5 axis induced by "pseudoviral" infection. Since chronic local activation of proinflammatory cytokines including TNF-α in resident renal cells may exist in patients with active lupus, synergistic effect of TNF-α and "pseudoviral" infection is possibly involved in the development of LN.                 

HIV vaccine hope found in immune system of a unique patient with a rare combination of HIV & SLE.


Scientists confirm gene mutation linked to lupus

Australian National University's Professor Chris Goodnow will test the controversial theory that autoimmune diseases may be caused by similar genetic mutations as benign lymphoma cancer after being awarded the $80,000 GlaxoSmithKline Award for Research Excellence.
The first stage of the research will involve patients with two particular autoimmune diseases, systemic lupus and Sjogren's syndrome.
Safety and pharmacodynamic results of rontalizumab in a phase i, placebo controlled, double blind, dose escalation study in systemic lupus erythematosus
Jacqueline M. McBride PhD1,Jenny Jiang MA1, Alexander R Abbas  PhD1, Alyssa Morimoto PhD1, Jing Li PhD1,Romeo Maciuca PhD1, Michael Townsend  PhD1, Daniel J. Wallace MD FACP FACR2, William P. Kennedy MD1, Jorn Drappa MD1  DOI:10.1002/art.34632
Copyright © 2012 by the American College of Rheumatology;jsessionid=9820893FA6E43B4D750228402B749757.d03t01
Wednesday, September 5, 2012
A new study called SKINDLE will test an  experimental skin ointment for active skin lesions caused by Discoid or Systemic Lupus Erythematosus. The drug, called R333, is a potent, topical JAK and SYK inhibitor with the potential to prevent or diminish both acute and chronic phases of this disorder. DLE is a chronic skin condition of sores with
inflammation and scarring favoring the face, ears, and scalp and at times on other body areas.
To view Rigel's animation on R333 in DLE, go to
Dr. Daniel Wallace, founder of Lupus LA and member of the S.L.E. Lupus Foundation’s Board of Directors, is conducting the study at the  Wallace Rheumatic Study Center in Los Angeles.
He can be contacted at 310-360-9197.